Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21M Sell
99,877
-1
-0% -$214 0.44% 51
2026
Q1
$22.1M Sell
99,878
-1,827
-2% -$447K 0.53% 47
2025
Q4
$25.8M Sell
101,705
-16,407
-14% -$4.12M 0.49% 43
2025
Q3
$29.2M Buy
118,112
+8,225
+7% +$1.97M 0.61% 40
2025
Q2
$26.4M Hold
109,887
0.58% 45
2025
Q1
$24.9M Hold
109,887
0.56% 44
2024
Q4
$22.6M Buy
109,887
+18,605
+20% +$4.08M 0.43% 56
2024
Q3
$22.1M Hold
91,282
0.36% 70
2024
Q2
$20M Buy
91,282
+17,848
+24% +$3.88M 0.33% 73
2024
Q1
$16.5M Buy
+73,434
New +$16.6M 0.25% 82

Other funds holding STE

Bellevue Group's STE Position: Q2 2026 in Review

Bellevue Group reduced its Steris (STE) stake by 0% in Q2 2026, selling an estimated $214 and leaving 99,877 shares worth $21M. The position accounts for 0.44% of the portfolio, ranked #51.

Bellevue Group first reported a position in STE in Q1 2024 and has held it in 10 quarters since. The position peaked at $29.2M in Q3 2025. 755 funds tracked by Wall St. Rank hold STE as of Q2 2026.

  • Bellevue Group held 99,877 shares of Steris worth $21M as of Q2 2026.
  • Bellevue Group sold 1 Steris share in Q2 2026, an estimated $214.
  • Steris made up 0.44% of Bellevue Group's portfolio in Q2 2026, its #51 holding.
  • Bellevue Group first reported a position in Steris in Q1 2024 and has held it in 10 quarters since.
  • Bellevue Group's Steris position peaked at $29.2M in Q3 2025.
  • 755 funds tracked by Wall St. Rank held Steris as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.